Partners Lisa Noller and Chris Donovan were quoted in a Law360 article, “Health Care Cases To Watch In 2020,” about a pending False Claims Act case over alleged fraud by hospice chain AseraCare Inc.
Noting that a federal judge had recently rejected a government bid to reopen discovery in the case, Noller, who chairs the firm’s national Government Enforcement Defense & Investigations Practice, said that “[w]ithout significant additional evidence, the case will be an uphill battle at trial.”
Donovan said health care providers facing similar FCA cases with inherently subjective diagnoses will now be pondering how they can “align those scenarios to the AseraCare case.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”